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Abstract
Despite limited evidence to support the use of amantadine to enhance cognitive function after traumatic brain injury (TBI),
the clinical use for this purpose is highly prevalent and is often based on inferred belief systems. The aim of this study was
to assess effect of amantadine on cognition among individuals with a history of TBI and behavioral disturbance using a
parallel-group, randomized, double-blind, placebo-controlled trial of amantadine 100mg twice-daily versus placebo for
60 days. Included in the study were 119 individuals with two or more neuropsychological measures greater than 1 standard
deviation below normative means from a larger study of 168 individuals with chronic TBI (>6 months post-injury) and
irritability. Cognitive function was measured at treatment days 0, 28, and 60 with a battery of neuropsychological tests.
Composite indices were generated: General Cognitive Index (included all measures), a Learning Memory Index (learning/
memory measures), and Attention/Processing Speed Index (attention and executive function measures). Repeated-
measures analysis of variance revealed statistically significant between-group differences favoring the placebo group at
day 28 for General Cognitive Index ( p = 0.002) and Learning Memory Index ( p = 0.001), but not Attention/Processing
Speed Index ( p = 0.25), whereas no statistically significant between-group differences were found at day 60. There were
no statistically significant between-group differences on adverse events. Cognitive function in individuals with chronic
TBI is not improved by amantadine 100mg twice-daily. In the first 28 days of use, amantadine may impede cognitive
processing. However, the effect size was small and mean scores for both groups were generally within expectations for
persons with history of complicated mild-to-severe TBI, suggesting that changes observed across assessments may not
have functional significance. The use of amantadine to enhance cognitive function is not supported by these findings.
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Introduction
Long-term cognitive impairment has been reported in upto 65% of individuals with moderate-severe traumatic brain
injury (TBI) with adverse effects on independence, homemaking
tasks, interpersonal relationships, leisure, employment, and other
aspects of life.1 In spite of limited evidence of efficacy, prescribing
pharmacological agents to improve chronic cognitive dysfunction
after TBI is common practice. The dopaminergic agent and N-
methyl-D-aspartate (NMDA) antagonist, amantadine (approved by
the U.S. Food and Drug Administration for influenza prevention
and Parkinson’s disease), is commonly used for this purpose.2
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Amantadine has a relatively benign side-effect profile (assuming
adequate renal function) compared to other agents. Although pre-
vious studies are limited by small sample size and design flaws,
preliminary evidence suggests some cognitive benefit from aman-
tadine. Notably, there is strong evidence that amantadine improves
rate of recovery acutely in those with severe TBI and prolonged
disorder of consciousness.3,4
Kraus and colleagues5 found a positive effect of amantadine on
executive function, but not attention and memory, in an open-label,
prospective study of 22 individuals with chronic TBI receiving
400mg of amantadine daily over 12 weeks. A retrospective study
by Reddy and colleagues6 studied amantadine use in 25 adolescents
whose cognitive function failed to return to baseline after 21 days of
rest after sports-related concussion. This cohort who received
amantadine 100mg twice-daily was compared to a cohort (matched
on age, sex, and concussion history) who were not treated with
pharmacological agents. This comparison found superior pre- to
post-test improvements in concussion symptoms (total score on 22-
item self-report symptom inventory), verbal memory, and reaction
time for the amantadine group, but no between-group differences
for visual memory and visual motor processing speed. In contrast, a
small (n= 10), double-blind, placebo-controlled, cross-over study
demonstrated no differences in the rate of cognitive improvement
(orientation, attention, executive function, memory, behavior, and a
composite variable) between patients treated with amantadine (100–
300 daily) and placebo during acute inpatient rehabilitation.7 In a
systematic literature review on dopaminergic agents for cognition
and agitation, Leone and colleagues8 concluded that amantadinemay
be a reasonable option to improve cognition and reduce agitation
after a TBI, but confirmatory evidence is needed. Despite the limited
evidence to support amantadine use to enhance cognitive function
after TBI, clinical use for this purpose is highly prevalent and is often
based on inferred beliefs. This common practice has been demon-
strated through data collected on prescribing patterns9,10 and a sur-
vey of brain injury physicians, which indicated that amantadine is a
popular pharmacological choice for treating memory impairment,
inattention, slow mental processing, and abulia.11
Given the common use of amantadine to enhance cognitive per-
formance after TBI and the limited evidence of efficacy, there is a
need for rigorous scientific evaluation of amantadine’s effect on
cognition. The Amantadine Irritability Multi-site Study (AIMS) was
a large, multi-site, randomized, placebo-controlled study performed
to assess the effect of amantadine on irritability (primary outcome)
and aggression, anger, and cognitive function (secondary out-
comes).12 The current study investigated the effect of amantadine on
cognitive function for participants in the AIMS study. Based on past
literature, we hypothesized that, compared to placebo, amantadine
(100mg every morning and noon) would significantly improve
cognitive function (overall cognitive performance, processing speed,
memory, attention, and executive function) from baseline assess-
ment to days 28 and 60.
Methods
Setting
Study sites were: Carolinas Rehabilitation in Charlotte, North
Carolina (lead site); Rehabilitation Hospital of Indiana (In-
dianapolis, IN); Kessler Institute of Rehabilitation (West Orange,
NJ); Spaulding Rehabilitation Hospital (Boston, MA); TIRR
Memorial Hermann (Houston, TX); The Ohio State University
(Columbus, OH); and University of Washington (Seattle, WA).
Study oversight
Institutional review board approval was received at each site, in-
formed consent obtained from all participants and their observers, and
the study registered on www.clinicaltrials.gov (#NCT00779324). An
external Data and Safety Monitoring Board provided independent
oversight. A data coordinating center (DCC) managed the concealed
treatment allocation, data storage, and data monitoring and, upon
study closure, transferred the data to the statistician.
Participants
Recruitment was through referrals, physician letters, and
newsletters. Individuals were eligible if 16–75 years of age, sus-
tained a nonpenetrating TBI at least 6 months prior to enrollment,
and obtained a score ‡6 on observer-rated Neuropsychiatric
Inventory–Irritability. TBI was verified by record review and cli-
nician interview as meeting at least one of the following criteria: 1)
post-resuscitation Glasgow Coma Scale (GCS) <13; 2) GCS Motor
<6 off paralytics; 3) loss of consciousness attributable to TBI; 4)
post-traumatic amnesia lasting ‡24 h; 5) neuroimaging consistent
with TBI; and/or 6) other evidence of TBI-related focal neurolog-
ical findings. An observer (family member, close friend, or em-
ployer) with adequate interaction to observe irritability was
required. Enrollment was further contingent upon medical and
neurological stability, ability to comply with study protocol, neg-
ative pregnancy test, and creatinine clearance >60. Individuals
were excluded if: 1) unable to interact and communicate; 2) threat
of harm to self or other; 3) history of neurologic disorder, schizo-
phrenia, or psychosis; 4) seizure in month preceding enrollment; 5)
concomitant use of typical neuroleptic agents or monoamine oxi-
dase inhibitors (because of potential drug interactions); and 6)
amantadine ingested during the month preceding enrollment. All
medications were on stable dosing for at least 1 month before en-
rollment with no plans to change medications during the 60-day
study. Active rehabilitation therapies, behavior treatments, and
counseling, if present, were started at least 1 month before enroll-
ment, and none were started during the study.We did not attempt to
record and compare groups on therapy involvement because both
rehabilitation and psychological therapies may vary considerably
in approach and quality among providers with no accepted method
Table 1. Neuropsychological Test Battery
Measure Cognitive functions measured
Digit Span, Wechsler Memory Scale–III14 Attention, working memory
Trail Making Test15 Alternating attention, visual-motor coordination
Controlled Oral Word Association Test (COWAT)16 Verbal fluency, executive function
California Verbal Learning Test-II (CVLT-II)17 Verbal learning and recall
WAIS-III Processing Speed Index
(PSI; comprised of Digit Symbol and Symbol Search)18,19
Attention, visual-motor coordination,
and psychomotor speed
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to quantify therapy impact. We relied on random assignment to
control for this and other potential group differences.
A sample of 168 was enrolled based on the sample needed to
replicate the study of the effect of amantadine on the primary
outcome (irritability).12 From the 168 study participants, a subset of
119 was selected with significant cognitive impairment as indicated
by two or more cognitive test scores at least 1 standard deviation
(SD) below normative values. Of this subset, 59 were in the
amantadine group and 60 in the placebo group.
Procedures
Demographic, medical history, and injury data were collected
and verified through interview and record review. Measures of
participant mood and behavior were administered to the participant
and the participant’s observer. Cognitive performance tests were
administered by trained study coordinators and audio recorded for
quality assurance review. After confirmation of eligibility and
baseline assessment, participants were randomly allocated 1:1 to
take amantadine (100mg every morning and noon) or placebo
equivalent. In cases of presumed drug intolerance, the dose was
reduced or terminated per pre-specified protocol. Participants and
observers completed the assessment measures at baseline and
treatment days 28 and 60.
Randomization and masking
The DCC conducted computer-generated block randomization
and concealed group allocation. After the site coordinators entered
the participant’s eligibility data into the study webpage and eligi-
bility confirmed, the DCC assigned a study number that indicated
which study drug kit to dispense. Randomization was stratified on
presence of depression at time of enrollment (<13 vs. ‡13 on the
Beck Depression Inventory [BDI]–II)13 based on possible associ-
ation of depression with irritability. The compounding pharmacist
and DCC had access to group assignment; all other study personnel,
participants, and observers were blinded to group allocation.
Measures
A battery of neuropsychological measures with well-established
psychometric properties was used14–19 (see Table 1). Scores from
these measures were converted to standardized scores using the
appropriate norm sets.
Other measures. Data were collected to characterize the
sample (see Table 2).
Statistical analysis
Analyses were performed using SAS statistical software (ver-
sion 9.3; SAS Institute Inc., Cary, NC).20 A two-tailed p value
<0.05 was considered statistically significant.
Cognitive performance composites were constructed by con-
verting each individual score to a sample percentile (i.e., the rank
divided by the number of available scores) and calculating the
mean percentile for each subject across all relevant measures.21 A
high score corresponded to a good outcome for all measures and
composites. (Note: Due to a few missing values, the overall sample
mean for each composite does not equal exactly 50.) The following
indices were created:
 Learning Memory Index (LMI): Comprised of the fol-
lowing California Verbal Learning Test (CVLT) mea-
sures: Trials 1–5 Total Score (T-score), Short Delay Free
Recall (Z score), Short Delay Cued Recall (Z score), Long
Delay Free Recall (Z score), and Long Delay Cued Recall
(Z score).
 Attention/Processing Speed Index (APSI): Comprised of
Digit Span (Scaled Score), Processing Speed Index, Trail
Making Test–A (T Score), Trail Making Test–B (T score),
and Controlled Oral Word Association Test (COWAT; T
score).
 General Cognitive Index (CGI): Comprised of measures in
LMI and APSI.
 Baseline Cognitive Index (BCI): Baseline CGI.
Table 2. Comparison of Demographic and Injury
Characteristics by Treatment Group
Characteristic Overall
Treatment group
Placebo Treatment Sig.
Subjects 119 60 59
Age, years
Mean (SD) 38.6 (12.4) 37.4 (12.2) 39.9 (12.6) 0.258
<40 67 (56%) 34 (57%) 33 (56%)
‡40 52 (44%) 26 (43%) 26 (44%)
Years post-injury
Mean (SD) 6.2 (5.5) 6.0 (5.1) 6.3 (6.0) 0.823
<5 64 (54%) 34 (57%) 30 (51%)
‡5 55 (46%) 26 (43%) 29 (49%)
Race
White 103 (87%) 52 (87%) 51 (86%) 1.000
Black 9 (8%) 4 (7%) 5 (8%)
Other 7 (6%) 4 (7%) 3 (5%)
Education years
Mean (SD) 13.3 (2.1) 13.3 (2.2) 13.3 (1.9) 0.983
A: Less than HS 11 (9%) 7 (12%) 4 (7%)
B: High school/GED 42 (35%) 19 (32%) 23 (39%)
C: Some college 49 (41%) 26 (43%) 23 (39%)
D: 4yr+ degree 17 (14%) 8 (13%) 9 (15%)
Primary activity
Student 8 (7%) 3 (5%) 5 (8%) 0.332
Competitively
employed
17 (14%) 11 (18%) 6 (10%)
Retired 51 (43%) 25 (42%) 26 (44%)
Unemployed 32 (27%) 18 (30%) 14 (24%)
Other 11 (9%) 3 (5%) 8 (14%)
Post-traumatic
amnesia
0: None 5 (4%) 2 (4%) 3 (5%) 0.709
1: 1–30min 3 (3%) 2 (4%) 1 (2%)
2: >30min to <1 day 1 (1%) 0 (0%) 1 (2%)
3: ‡1 day 104 (92%) 53 (93%) 51 (91%)
Unknown 6 3 3
Loss of consciousness
0: None 9 (8%) 6 (10%) 3 (5%) 0.192
1: 1–30min 11 (10%) 6 (10%) 5 (9%)
2: >30min to <1 day 14 (12%) 9 (15%) 5 (9%)
3: ‡1 day 81 (70%) 39 (65%) 42 (76%)
Unknown 4 0 4
Depression
BDI <13 38 (32%) 19 (32%) 19 (32%) 1.000
BDI ‡13 81 (68%) 41 (68%) 40 (68%)
SD, standard deviation; HS, high school; GED, General Educational
Development; BDI, Beck Depression Inventory.
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Treatment groups were compared on baseline characteristics and
BCI. For ordinal variables, the normal approximation for the
Wilcoxon rank-sum test was used. For categorical variables,
Fisher’s exact tests were used.
Analyses were performed using the intention-to-treat principle.
Pre-specified outcome analyses included: 1) comparison of the
change in cognitive performance scores from baseline to day 28 and
baseline to day 60 and 2) comparison of the change in cogni-
tive indices (GCI, LMI, and APSI) from baseline to day 28 and
baseline to day 60 using linear mixed-effects modeling, where
each subject was modeled with a random slope and intercept, time
was treated as categorical, and no other covariates were included
in the models.
Results
Participants
From August 2009 to April 2013, 168 individuals (enrollment
target for irritability outcome) were enrolled and randomized, with
119 meeting criteria for cognitive impairment (60 placebo and 59
amantadine) as outlined in Figure 1.8 Compliance, defined as ‡80%
prescribed study drug consumed per pill count, was high (88.5% in
amantadine group and 86.9% in placebo group). Eleven partici-
pants (6.6%; 4 placebo and 7 amantadine) did not complete the
study. On rare occasions, study participants were unable to com-
plete the cognitive tests (e.g., inability to present in-person). Sup-
plementary Digital Content Table (see online supplementary
material at http://www.liebertpub.com) provides an inventory of
neuropsychological measure availability (sample size) for each
treatment group by assessment interval.
Table 2 summarizes and compares the baseline demographic and
injury characteristics of the amantadine and placebo groups.
Groups were well matched with respect to baseline factors. Table 3
compares the baseline scores for the neuropsychological test vari-
ables by treatment group. Baseline scores for the placebo group
were slightly lower than that for the treatment group, but only PSI
was nominally significant ( p = 0.048).
Treatment group comparisons
The unadjusted standardized scores and change from baseline
are displayed in Table 3 sorted by assessment interval and treatment
group. At day 28, the mean change for the placebo group demon-
strated greater improvement than for the amantadine group for all
the measures except Digit Span and COWAT. Because change
from baseline was apparent at day 28 on the memory measures but
not the nonmemory measures, we examined the degree of change
on individual memory tests included in the CVLT. A high percent
of those in the placebo group showed positive change from baseline
to day 28 (59–65%) compared to the amantadine group (46–53%)
on all CVLT measures. Note that except for baseline measures in
the placebo group, all scores for both groups were within normal
limits defined as within 1 SD of the normative group mean.
Results of the mixed-effects linear regression modeling of the
cognitive indices are summarized in Table 3. Greater improvement
in GCI (6.2 percentiles; 95% confidence interval [CI], 2.3–10.1;
p = 0.002) and LMI (10.2; 95% CI, 4.0–16.3; p= 0.001) was found
for the placebo group compared to the amantadine group at day 28.
Improvement in APSI did not significantly differ between the
groups ( p= 0.250). At day 60, no significant between-group dif-
ferences were observed for any of the indices.
Adverse events
Amantadine was well tolerated among study participants with no
significant between-group differences on withdrawals/lost or ad-
verse events (using Fisher’s exact test). Adverse events are sum-
marized elsewhere.12
Discussion
This is the largest study to examine the effect of amantadine on
cognitive performance in chronic TBI. In this chronic (>6 months)
TBI sample with behavioral disturbance, both amantadine and
placebo groups showed improvement on the cognitive measures
and indices, with several memory measures demonstrating superior
improvements in the placebo group at day 28. No significant group
differences were found at day 60. Such significant placebo effects
can be observed in chronic populations, but the difference suggests
a marginally negative impact of amantadine on cognition.22
Both groups showed increases in normed scores on memory
measures from baseline to day 28 and day 28 to day 60, likely
attributed to practice effects. On most tests, the placebo group
started from a nonsignificantly lower baseline. However, control-
ling for baseline, the placebo group showed slightly greater im-
provement on both GCI and LMI from baseline to day 28 compared
to the treatment group, amounting to approximately 0.25 SD.
However, by day 60, any difference in the amount of change from
baseline between the two groups on memory measures was negli-
gible. The most straightforward explanation could be that aman-
tadine in the treatment group caused a temporary decrease in the
expected practice effect on these memory measures, but by day 60,
this temporary practice effect inhibition resolved so that both
groups had equivalent practice effect from baseline to day 60.
Alternatively, amantadine may have acted on limbic instability in
this population with behavioral dysregulation, possibly down-
regulating behavioral and cognitive processing. In theory, aman-
tadine might help mediate mesolimbic circuit regulation through
dopaminergic mechanisms and impact behavior. However, the
impact of amantadine on new learning and long-term potentiation is
less clear given that these functions could be negatively impacted
by amantadine’s NMDA receptor antagonism.23 Other potential
mechanisms include induction of depression and altered striatal
plasticity.24 It is unlikely that a ceiling effect inhibited the practice
effect in the amantadine group at 28 days given that this group
continued to achieve higher scores at 60 days, and at 60 days re-
asserted their advantage observed at baseline.
The community-dwelling sample studied here was significantly
impaired as demonstrated in Table 3. Themean onmost tests for the
sample is greater than 1.5 SD below the normative mean at base-
line, suggesting that a substantial proportion of the sample scored
even lower on these tests. It is possible that an extremely cogni-
tively impaired population requiring residential care might respond
to amantadine.
Although LMI improvement was superior for the placebo
group, the effect may not have been specific to learning and
memory. Learning and memory are dependent on other functions,
such as distractibility or fatigue with extended cognitive tasks,
which may have contributed to the transient reduction in cognitive
functioning in the treatment group. Other than assuring that
medications were not added or dosage changed during the study,
we did not control for the use of other drugs, which may have
affected our findings. Additionally, a constant challenge in
chronic TBI intervention studies is the heterogeneous nature of
the injuries. In future studies, it would be interesting to evaluate
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FIG. 1. Participant flow diagram. SD, standard deviation.
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other markers of brain function, including blood flow or inflam-
mation, to further characterize the participants and evaluate the
brain’s ability to respond to stimuli.
From a clinical standpoint, any neurostimulant or other neuro-
modulatory treatment may not be effective without additional
directed therapy to practice the targeted cognitive ability. Aman-
tadine has been shown to accelerate functional outcome acutely
in minimally conscious state and vegetative state3,4 and improve
irritable and aggressive behavior in chronic TBI.12,25 The risk-
benefit profile of deciding on treatment will be different for each
individual.
Taken together, these findings provide no evidence to support
the prevailing belief that amantadine at 100mg twice-daily dosing
improves overall cognitive function, learning memory, attention,
and processing speed in patients with chronic TBI, as measured by
the neuropsychological measures used in this study. Only a couple
of small studies have looked at the effect of amantadine on cog-
nition previously. These earlier studies, using 200–400mg/day, had
mixed results. Along with our findings, studies to date provide no
consistent evidence of amantadine’s efficacy for improving overall
cognitive function or specific aspects of cognitive function in in-
dividuals with complex mild-to-severe TBI. It would be useful,
however, to reproduce this study in children and adolescents.
This study reports solely on changes on neuropsychological
measures and does not include other means of function. The co-
hort’s response of amantadine in respect to neurobehavioral
Table 3. Comparison of Neuropsychological Test Variables by Treatment Group at Baseline and Linear
Modeling of All Outcome Measures for the Cognitively Impaired Sample (n = 119)
Outcome measure Day
Raw scores Linear modela
Placebo Treatment Difference
Change
from
baseline
Model-
adjusted
change Sig. 95% CI
Rey (T) 0 34.5 37.7 3.16
28 41.7 41.1 –0.58 –3.74 –3.62 0.045 (-7.16, -0.08)
60 43.5 46.9 3.45 0.29 –0.46 0.801 (-4.05, 3.13)
Short Delay Free (Z) 0 –1.43 –1.32 0.11
28 –0.94 –1.01 –0.07 –0.18 –0.21 0.231 (-0.55, 0.13)
60 -0.77 –0.63 0.15 0.04 –0.06 0.720 (-0.41, 0.29)
Short Delay Cued (Z) 0 –1.43 –1.30 0.13
28 –0.91 –1.01 –0.10 –0.22 –0.25 0.154 (-0.58, 0.09)
60 –0.71 –0.60 0.11 –0.01 –0.12 0.482 (-0.47, 0.22)
Long Delay Free (Z) 0 –1.66 –1.45 0.21
28 –1.00 –1.16 –0.16 –0.37 –0.40 0.020 (-0.73, -0.06)
60 –0.88 –0.79 0.09 –0.12 –0.24 0.171 (-0.58, 0.10)
Long Delay Cued (Z) 0 –1.58 –1.44 0.13
28 –0.95 –1.08 –0.13 –0.27 –0.28 0.074 (-0.59, 0.03)
60 –0.71 –0.64 0.06 –0.07 –0.20 0.216 (-0.51, 0.12)
Digit Span 0 8.47 8.75 0.28
28 9.02 9.07 0.06 –0.22 –0.14 0.670 (-0.76, 0.49)
60 8.95 9.27 0.33 0.05 0.13 0.682 (-0.50, 0.77)
PSI 0 78.5 83.0 4.53
28 83.6 85.9 2.34 –2.19 –1.33 0.299 (-3.85, 1.19)
60 84.5 88.8 4.36 –0.17 0.14 0.914 (-2.42, 2.71)
Trail A (T) 0 36.4 39.8 3.46
28 40.3 42.0 1.69 –1.78 –0.85 0.625 (-4.25, 2.56)
60 41.9 45.0 3.14 –0.32 –0.25 0.888 (-3.71, 3.22)
Trail B (T) 0 37.6 39.5 1.93
28 41.4 41.0 –0.35 –2.28 –1.20 0.522 (-4.91, 2.50)
60 40.1 42.5 2.34 0.41 0.37 0.846 (-3.38, 4.13)
COWAT 0 37.6 36.3 –1.36
28 38.8 38.5 –0.26 1.10 1.34 0.251 (-0.95, 3.63)
60 39.5 39.9 0.42 1.79 2.12 0.074 (-0.21, 4.45)
Overall Composite (GCI) 0 47.3 52.7 5.37
28 50.6 49.2 –1.39 -6.76 –6.24 0.002 (-10.14, -2.34)
60 48.3 51.9 3.58 –1.79 –2.62 0.195 (-6.59, 1.35)
Learning/ Memory Index (LMI) 0 46.7 53.4 6.69
28 51.5 48.3 –3.20 –9.90 –10.16 0.001 (-16.32, -4.00)
60 48.4 51.9 3.49 –3.20 –5.37 0.093 (-11.63, 0.90)
Attention/ Processing Speed Index (APSI) 0 48.0 52.0 4.04
28 49.6 50.2 0.57 –3.46 –2.11 0.250 (-5.71, 1.49)
60 48.2 51.9 3.67 –0.36 0.26 0.889 (-3.41, 3.93)
Bolded font indicates that the result remained statistically significant ( p < 0.05) after adjusting for multiple comparisons (Holm-Bonferroni, m= 26).
aMixed-effects linear regression model, treating subject as random and time as categorical, with no other model covariates. Reported model statistics
correspond to the time-by-treatment interaction. Positive change scores indicate a positive treatment effect.
CI, confidence interval.
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function has been reported elsewhere.12,25 A study of the effect of
amantadine on recovery of consciousness in patients with acute
TBI (median 47 or 48 days post-injury)3 found that patients treated
with amantadine showed more rapid improvement in responsive-
ness than those treated with a placebo, with no group differences
after a washout period. A smaller study (n= 35) of individuals with
acute TBI found greater improvements in Mini-Mental Status,
Disability Rating Scale, GCS, and Functional Independence Mea-
sure who received amantadine 200mg as compared to placebo for 6
weeks from time of injury to up to 12 weeks post-injury in a cross-
over design.26 Perhaps there is a critical interval early post-injury
during which treatment with amantadine improves consciousness
even if this advantage is short-lived. Such an effect would not have
been detected in the current investigation with randomization an
average of 6 years post-injury. Certainly, arousal and consciousness
differ from cognitive function, and amantadine would be expected
to differentially impact these functions.
Of note, the date of injury for this cohort occurred up to as early
as 6 months post-injury. Given that cognitive and neurobehavioral
improvements may continue over the years post-injury, we do not
know to what extent these individuals have or have not reached a
cognitive and/or neurobehavioral plateau. Whereas the study en-
rolled individuals up to 6 months post-injury, the average time
post-injury was 6.2 years (5.5 SD), with 46%more than 5 years post-
injury.27 If the study had found positive changes post-injury, it is
reasonable to ask how much is attributed to natural recovery versus
howmuch is attributed to amantadine. However, in this study, which
did not find positive change in cognitive function, the issue of on-
going recovery/change is not an explanation for our findings.
Limitations
An evaluation of the effect of amantadine on cognition was not
the primary focus of this study. Participants were not screened for a
particular level of cognitive impairment. This resulted in a cohort
that was probably performing at expectation for persons with his-
tory of complicated mild-to-severe TBI. If we had screened for
persons with greater than typical cognitive impairment in the
chronic period after TBI, our study may have provided a more
useful test of the possible effect of amantadine on cognitive im-
pairment. Additionally, by selecting those with behavioral distur-
bance, the benefit may have focused on behavioral dysfunction at
the price of cognitive processing perhaps by regulating limbic
function. Last, the heterogeneity of the group may have impacted
the results, and those with either more-severe or less-severe pat-
terns of deficits or specific biological patterns may have represented
a better focused target.
Conclusion
This is the largest known clinical trial to assess the effect of
amantadine on cognitive function among individuals with chronic
TBI. Amantadine 100mg twice-daily in this population with
chronic TBI appears not to be beneficial for overall cognition.
Amantadine may have a small, transient negative impact on cog-
nitive functioning during the first month of treatment. The use of
amantadine to enhance cognitive function is not supported by the
study findings.
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